With the Federal Reserve continuing to hike interest rates rather than cut them, floating rate ETFs like the State Street SPDR Blackstone Senior Loan ETF (SRLN) have become attractive fixed income options. SRLN provides a 7.19% SEC yield, near-zero duration, and a quick rate reset period of 31 days, allowing distributions to reflect new Fed hikes rapidly. Loan default rates remain stable, and without a recession, borrowers are expected to keep up payments, supporting returns estimated above 5%. This makes SRLN a recommended buy for investors seeking sustainable income, though caution is advised for unforeseen negative shocks.
The story on floating rate ETFs like SRLN is presented alongside Pluang's market snapshot as of Oct 24, 2026 19:01 WIB: out of 150 US stocks priced on Pluang, 46 rose and 102 fell. Among notable movers, BlackBerry Limited (BB) gained 3.84% at USD 8.92 with a typical hold time of 51 days, contrasting with American Airlines Group Inc (AAL) which dropped 3.89% to USD 12.11 and a hold time of 59 days. American Express Co (AXP) also declined by 3.68% to USD 313.03, held typically for 124 days.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
